https://www.selleckchem.com/products/pnd-1186-vs-4718.html 64, 95% CI=0.45-0.90, p=0.010). Haplotype analysis revealed that A T haplotype of CYP3A4 was found to increase the risk of COPD in non-smokers (OR 1.71, 95% CI=1.04-2.82, p=0.034). Our result gives a new understanding of the association between CYP3A4 gene and COPD in the Hainan Han population. Our result gives a new understanding of the association between CYP3A4 gene and COPD in the Hainan Han population. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) might contribute to brain inflammation after acute brain injury. The current study was designed to investigate whether serum soluble TWEAK (sTWEAK) can serve as a potential biomarker for functional outcome after aneurysmal subarachnoid hemorrhage (aSAH). In this single-center prospective, observational study, admission serum sTWEAK concentrations were quantified among 112 aSAH patients. Impact of serum sTWEAK concentrations on a poor outcome (Glasgow outcome scale score 1-3) at 6months after stroke onset was determined using multivariate analysis. Admission serum sTWEAK concentrations were intimately correlated with serum C-reactive protein concentrations, World Federation of Neurological Surgeons scores and modified Fisher scores. A total of 38 patients (33.9%) had a poor outcome at post-hemorrhagic 6months. Admission serum sTWEAK concentrations were substantially higher in patients with a poor outcome than in the other remainders. Under receiver operating characteristic curve, serum sTWEAK concentrations significantly distinguished a poor outcome. Serum sTWEAK concentrations>3.23ng/ml discriminated the risk of a poor outcome with medium-high sensitivity and specificity and independently predicted a poor outcome. Serum sTWEAK, in close correlation with inflammation and hemorrhagic severity, might represent a potential biomarker for predicting clinical outcome after aSAH. Serum sTWEAK, in close correlation with inflammation and hemorrhagic sever